Total Health

 

Total Health is the largest provider of free cancer care resources for people who are treating or living with cancer. Our programs arm cancer care teams with the latest research and strategies to improve patient outcomes.

For more info visit our website at Total Health.

 

2020 Virtual ESMO Review
05:09

2020 Virtual ESMO Review

2020 ESMO Update on R/R DLBCL: Does AUTO3 + Pembro Induce CRs? What Are the Outcomes of Pts With HIV Receiving High-Dose Chemotherapy?

FEATURING Jennifer Amengual
  • 14 views
  • December 3, 2020
07:49

2020 Virtual ESMO Review

2020 ESMO Update on R/R cHL: How Effective Is Brentuximab Vedotin?

FEATURING Jennifer Amengual
  • 46 views
  • December 3, 2020
06:52

2020 Virtual ESMO Review

2020 ESMO Update on Non-Hodgkin Lymphomas: Does BETi CC-90010 Lead to Clinical Responses in R/R DLBCL? How Effective Is LSD1 Inhibitor CC-90011 MZL?

FEATURING Jennifer Amengual
  • 12 views
  • December 3, 2020
07:33

2020 Virtual ESMO Review

2020 ESMO Update on Targeted Therapy in NSCLC: Does ADAURA Trial Suggest Clinically Meaningful Improvement in CNS DFS With Osimertinib? Does Heavily Pretreated KRAS G12C-Mutant NSCLC Respond to Sotorasib?

FEATURING Ibiayi Dagogo-Jack
  • 167 views
  • November 25, 2020
05:44

2020 Virtual ESMO Review

2020 ESMO Update on Targeted Therapy in NSCLC: Can We Safely Combine Amivantamab + Lazertinib in Advanced EGFR+ Disease?

FEATURING Ibiayi Dagogo-Jack
  • 22 views
  • November 25, 2020
06:52

2020 Virtual ESMO Review

2020 ESMO Update on UC: Does 1L Durvalumab +/- Tremelimumab Improve OS vs. SoC Chemo in Unresectable Advanced UC? Can Sacituzumab Govitecan Change Practice in mUC?

FEATURING Manojkumar Bupathi
  • 39 views
  • November 16, 2020
08:30

2020 Virtual ESMO Review

2020 ESMO Update on RCC: Is IO + TKI Option Effective in Advanced Disease? Is ctDNA Analysis Feasible and Highly Concordant With Tissue Genomic Analysis and Can It Guide Treatment Selection in mRCC?

FEATURING Manojkumar Bupathi
  • 205 views
  • November 16, 2020
  • 2
07:47

2020 Virtual ESMO Review

2020 ESMO Update on Advanced UC: Does the Addition of Avelumab 1L Maintenance to BSC in Advanced Disease Affect on Clinically Relevant PROs? Is There More PFS/OS Benefit Upon the Addition of Pembro to Chemo?

FEATURING Manojkumar Bupathi
  • 65 views
  • November 16, 2020
11:16

2020 Virtual ESMO Review

2020 ESMO Update on ALK+ NSCLC: PFS Data With Lorlatinib vs. Crizotinib - Should We Consider Lorlatinib a New 1L Option?

FEATURING Ibiayi Dagogo-Jack
  • 226 views
  • November 11, 2020
  • 2
20:42

2020 Virtual ESMO Review

ESMO 2020 Update on mPC: How Beneficial Is Abiraterone+/-Ipatasertib for rPFS? Does PSMA-Targeting AMG160 BiTe Offer Good Duration of Response? Can Metformin Delay Disease Progression?

FEATURING Tanya Barauskas Dorff
  • 78 views
  • November 9, 2020
33:00

Total Health

Will COVID-19 Leave Its Mark on Cancer Care?

FEATURING Gilberto Lopes
  • 1,815 views
  • November 6, 2020
  • 6
08:53

2020 Virtual ESMO Review

2020 ESMO Updates on Pembrolizumab & Cemiplimab: Can mNSCLC Be Cured With Immunotherapy?

FEATURING Martin Dietrich
  • 591 views
  • November 4, 2020
  • 5
06:15

2020 Virtual ESMO Review

2020 ESMO First Results from PIONeeR Project on Biomarkers in Advanced NSCLC: Can Biomarker Analysis Predict Response/Resistance to ICIs?

FEATURING Martin Dietrich
  • 507 views
  • November 4, 2020
  • 1
09:56

2020 Virtual ESMO Review

2020 ESMO Updates in Lung Cancer: Does 1L Nivolumab–Ipilimumab Boost Unresectable Mesothelioma OS? Did the PACIFIC Trial Demonstrate Durable Benefit With Durvalumab After cCRT in Stage 3 NSCLC?

FEATURING Martin Dietrich
  • 608 views
  • November 4, 2020
  • 1
07:30

2020 Virtual ESMO Review

2020 ESMO Update on MBC: Is There OS Benefit to Alpelisib + Fulvestrant in PI3KCA-Mutated HR+ MBC? Does Sacituzumab Govitecan Improve PFS & OS Over Standard Chemotherapy in mTNBC?

FEATURING Jennifer Crozier
  • 113 views
  • November 4, 2020
  • 1
10:12

2020 Virtual ESMO Review

2020 ESMO Update on MBC: Does the Addition of Tamoxifen to Abemaciclib Provide OS Improvement in HR+ Disease? Is TMB Associated With Improved Outcomes With 1L Atezolizumab + Nab-Paclitaxel in mTNBC?

FEATURING Jennifer Crozier
  • 515 views
  • November 4, 2020
  • 1
08:19

2020 Virtual ESMO Review

2020 ESMO Update on Immune Checkpoint Inhibitors in eTNBC: Does the Addition of Atezolizumab to Chemotherapy Improve pCR Rate in Neoadjuvant Setting?

FEATURING Lee Schwartzberg
  • 372 views
  • November 4, 2020
  • 4
06:06

2020 Virtual ESMO Review

2020 ESMO Update on CDK 4/6 in Adjuvant HR+, HER2- EBC: Does the Addition of Abemaciclib to Hormonal Therapy Reduce the Risk of Cancer Recurrence?

FEATURING Lee Schwartzberg
  • 174 views
  • November 4, 2020
07:46

2020 Virtual ESMO Review

2020 ESMO Update on CDK 4/6 in Adjuvant HR+, HER2- EBC: How Does Two Years of Adjuvant Palbociclib With ET Compare to ET Alone?

FEATURING Lee Schwartzberg
  • 191 views
  • November 4, 2020
  • 1
13:27

2020 Virtual ESMO Review

2020 ESMO Update on mPDAC: Does the Addition of Dual Immune Checkpoint Inhibitors to Gem and Nab-p Result in Improved OS, PFS, or ORR?

FEATURING Louise Connell
  • 222 views
  • November 4, 2020
  • 1
08:07

2020 Virtual ESMO Review

2020 ESMO Update on Metastatic Pancreatic Cancer: What Does the QoliXane Trial Data Suggest on Time to Deterioration of QoL in Patients Treated With 1L Nab-Paclitaxel?

FEATURING Louise Connell
  • 58 views
  • November 4, 2020